Introduction {#s0005}
============

Obesity is now one of the major public health problems facing the world. In 2005, 400 million adults were obese, and this is projected to increase to 700 million by 2015 ([www.who.int](http://www.who.int){#ir0015}). This "epidemic" has prompted major scientific efforts to determine the mechanisms underlying the regulation of food intake in order to facilitate the development of effective therapies for obesity. A particular focus has been applied to nutrient-induced gut-to-brain signalling mechanisms. In human research, the development of blood-oxygenation-level-dependent (BOLD) functional magnetic resonance imaging (fMRI) has resulted in the identification of a number of homeostatic and non-homeostatic brain regions associated with the regulation of appetite ([@bb0045]). However, to date, the focus of these human studies has largely been the evaluation of higher centre cognitive responses to food cues (such as images of palatable food), rather than the physiological responses to meal ingestion. The more recent application of the physiological MRI (physMRI) technique ([@bb0075; @bb0085]) has allowed the exploration of BOLD signal responses to nutrients over time across the whole brain, in particular, in key areas involved in the regulation of food intake such as the brainstem and hypothalamus.

It is well established that the presence of glucose in the small intestinal lumen is associated with decreased hunger, increased fullness, and decreased energy intake at a subsequent meal ([@bb0025; @bb0090; @bb0155]), but the brain centres and transduction mechanisms underlying these effects are poorly defined in humans. Animal studies have identified the hypothalamus as a critical region for the regulation of energy balance ([@bb0010; @bb0060]), and in man, a number of fMRI studies have reported that oral glucose decreases hypothalamic BOLD signal, relative to water ([@bb0125; @bb0170; @bb0175; @bb0180; @bb0195]). However, these studies did not investigate the responses of other sub-cortical brain regions to glucose, and the movement of the head during consumption of oral meals induced imaging artefacts that precluded evaluation of the early responses. In particular, detailed imaging of the human brainstem has not been reported and is critical as it is the first relay point responsible for integrating neural signals transmitted from the upper gut via vagal afferent neurons.

The mechanism by which the presence of glucose in the gut is signalled to the human central nervous system is likely to involve an interaction between direct responses to elevated circulating glucose concentrations ([@bb0100]), and indirect responses via glucose sensitive neural (e.g. vagal), or endocrine signalling pathways (e.g. insulin ([@bb0125; @bb0175]) and/or gut derived peptides, such as cholecystokinin (CCK) ([@bb0085; @bb0115]) and glucagon-like peptide-1 (GLP-1) ([@bb0150])). Recent studies have indicated that signals arising from the gastrointestinal tract are likely to play an important role in mediating the hypothalamic response to glucose. For example, the effect of glucose on hypothalamic BOLD signal has been reported to be greater when administered orally compared to intravenously ([@bb0180]). The hypothalamic response has also been related to fasting insulin concentrations ([@bb0125; @bb0130]), and additionally a relationship has been found between postprandial plasma GLP-1 concentrations and increases in BOLD signal in the left dorsolateral prefrontal cortex and the hypothalamus, following ingestion of a liquid meal ([@bb0150]). However, in these previous studies, whole brain responses, and time courses of the response could not be evaluated.

Using physMRI to investigate whole brain responses, we have previously shown that intragastrically administered lipid (the fatty acid, lauric acid (C12)) increases BOLD signal in key human brain areas, including the brainstem and hypothalamus ([@bb0085]). These activations were abolished by the administration of the CCK~1~ receptor antagonist, dexloxiglumide ([@bb0085]), and modulated by ghrelin ([@bb0075]).

We, therefore, decided to apply the same imaging technique to identify and define the brain regions responsive to glucose. Like lipid, glucose ingestion is known to slow gastric emptying ([@bb0070]), and to induce gallbladder contraction ([@bb0030]). In addition, dexloxiglumide attenuates the inhibitory effects of glucose on gastric emptying ([@bb0040; @bb0115]), suggesting that CCK is also involved in this, and possibly mediating the gut-to-brain signalling response to glucose. Therefore, the CNS response to different macronutrients may be predicted to have significant overlaps.

This study therefore had two aims: first, to determine whether intragastric glucose would induce changes in BOLD signal in the same nutrient-sensitive regions, robustly observed in response to lipid, namely the brainstem and hypothalamus, and second, to determine whether any effects of glucose observed in the CNS were also CCK~1~ receptor-dependent.

Methods {#s0010}
=======

Subjects {#s0015}
--------

12 healthy volunteers (7 males, mean (SEM) age: 38 (3.4) (range: 23--60) years) with a non-obese body mass index (BMI: 24 (1) (range: 19.7--28.9) kg/m^2^) were recruited from the staff and local population of Salford Royal NHS Foundation Trust. Exclusion criteria comprised: presence of any gastrointestinal, endocrine or metabolic disease; consumption of medications that may affect gastrointestinal function, sensation or appetite; metallic implants or objects (e.g. hearing aid, pacemaker), and consumption of greater than 20 g of alcohol or 10 cigarettes/day. All were instructed to abstain from alcohol and vigorous physical activity for 24 h prior to the study. In both the gastric emptying and the fMRI study arms, participants were blinded both to the nature of the intragastric infusions, and to the drug, and studies were performed in a randomised order. Randomisation was performed using a random number generator. Participants provided informed written consent. The study was approved by the Salford and Trafford Research Ethics Committee, and was carried out in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) and the standards established by the author\'s ethics committee and granting agency. All participants provided informed, written consent after the nature of the experimental procedures provided in writing.

Materials {#s0020}
---------

[d]{.smallcaps}-Glucose was purchased from Sigma-Aldrich (Gillingham, England). The CCK~1~ receptor antagonist, dexloxiglumide (300 mg tablets), and matched placebo tablets were supplied at no cost by Rottapharm (Monza, Italy) as a scientific collaboration.

Gastric emptying protocol {#s0025}
-------------------------

As the medulla houses the sensory and motor nuclei responsible for relaying vago-vagal enteric circuits, as well as signalling to higher centres, we used the measurement of changes in gastric emptying induced by glucose as a convenient proxy measure to identify a dose of glucose that would have effects on brainstem BOLD response ([@bb0115]). Participants arrived at the laboratory at 09:00 h after an overnight fast from 22:00 h and orally ingested either 600 mg of dexloxiglumide (1 occasion), or matched placebo (2 occasions), tablets. Previous studies in our laboratory have demonstrated that this dose effectively blocks the effects of lipid (lauric acid (C12)) ([@bb0080]) and glucose ([@bb0115]) on gastric emptying, and the effect of lipid on BOLD signal in the brainstem and hypothalamus ([@bb0085]). One hour later, a nasogastric feeding tube was positioned, with its distal tip in the stomach. Gastric delivery was employed to eliminate sensory or hedonic effects of oral sweet tasting, and for the MRI studies, movement artefacts during drinking and swallowing. A basal, end-expiratory, breath sample was collected; following which participants received a bolus intragastric infusion of 250 ml glucose (45 g, 180 kcal, 1000 mOsmol) or 250 ml of water (volumetric control). Each meal was labelled with 100 mg ^13^C-sodium acetate, used as a marker for gastric emptying (CK Gas Products Ltd., UK). For the assessment of gastric emptying rate, end-expiratory breath samples were collected at 5 minute intervals over a period of 45 min ([@bb0120; @bb0115]). On each occasion, the subject exhaled through a mouth-piece to collect an end-expiratory breath sample into a 100 ml foil bag, which was then sealed with a plastic stopper, and stored for later analysis.

Breath samples were analysed by non-dispersive infrared spectroscopy (IRIS, Wagner Analysen Technik, Bremen, Germany). This enabled evaluation of the isotopic composition of carbon in the expired carbon dioxide (CO~2~) by determination of the ratio of ^13^C:^12^C in the sample ([@bb0095; @bb0165]). ^13^C-acetate is rapidly absorbed and metabolized after it is emptied from the stomach, hence the rate of appearance of ^13^CO~2~ in the systemic circulation closely corresponds to the rate of GE ([@bb0165]).

physMRI protocol {#s0030}
----------------

12 participants were studied on three separate occasions at 08:30 h following an overnight fast from 22:00 h, to evaluate the spatiotemporal pattern of brain activation in response to intragastric infusion of: (i) glucose (250 ml, 1000 mOsmol (45 g glucose, 180 kcal)) following two placebo tablets, (ii) glucose (250 ml, 1000 mOsmol) following the CCK~1~ receptor antagonist, dexloxiglumide (600 mg (two 300 mg tablets)) (glucose + dex), and (iii) 0.9% saline (control) following two placebo tablets. The dexloxiglumide (condition ii), or matched placebo, tablets (conditions i and iii), were orally ingested with 100 ml of water 1 h prior to the commencement of the intragastric infusion. All conditions were matched exactly to our previous studies ([@bb0075; @bb0085]) to enable direct comparison between the glucose- and lipid-induced nutrient matrices. In the study design we purposefully omitted a saline + dex control arm since we had previously demonstrated, under the same study conditions (i.e. after an overnight fast and with identical imaging parameters), that there was no effect of dexloxiglumide in the absence of nutrient (i.e. during intragastric saline infusion) on BOLD signal across the whole brain ([@bb0085]). Furthermore, dexloxiglumide has no effect on the gastric emptying of water/saline ([@bb0115]). Due to the large number of statistical comparisons to be performed, which do not require the placebo/placebo condition, and mindful of burden on experimental subjects, we considered that repeating this was unjustified.

Thirty minutes prior to scanning, participants were intubated with a nasogastric feeding tube and an intravenous cannula was positioned in an antecubital vein to enable repeated blood sampling. Participants were then positioned in the scanner (3.0 T Philips Achieva MR System, Magnetic Resonance Imaging Facility (MRIF), Salford Royal NHS Foundation Trust) and images of the gallbladder acquired. Immediately following this, participants were repositioned in the scanner for the 30 minute fMRI scan. After a baseline period of 4 min, the intragastric infusion (glucose or saline) was administered as a bolus, using a syringe via the nasogastric tube, over a period of 1 min. Subjective ratings of fullness, hunger and nausea were recorded every 5 min throughout the scan. Venous blood samples were taken to assess blood glucose, and plasma insulin, CCK and GLP-1 concentrations at the start of the scan protocol (t = 0 min), and then at t = 5, 10, 15, 20, and 25 min following the intragastric infusion. After the fMRI scan, a second gallbladder image was acquired. On the first visit, participants were positioned in the scanner an additional 10 min before the commencement of the scanning protocol to enable a high-resolution structural scan to be performed to more accurately normalise each individual\'s brain anatomy.

Gallbladder MR acquisition and volume measurement {#s0035}
-------------------------------------------------

Gallbladder volume, which is a classical *in vivo* bioassay for CCK activity, was determined to evaluate the functional significance of the CCK response to the glucose test meals and as a positive control for CCK~1~ receptor blockade by dexloxiglumide ([@bb0110]). Complete blockade of gallbladder contraction demonstrates effective CCK~1~ receptor antagonism. Volumes were determined from single-shot, T2 weighted axial, coronal and sagittal 3 T anatomical MR images of the upper abdomen obtained at the beginning and end of each study using a SENSE torso coil triggered by respiration. Gallbladder volume was estimated using the ellipsoid method, whereby volume = length × depth × width × 0.523 (where π/6 = 0.523, depth = maximum antero-posterior diameter and width = maximum lateral diameter) ([@bb0035; @bb0085]).

Sensation scores {#s0040}
----------------

Subjects were asked to indicate their sensations of hunger, fullness and nausea on a 10 point scale, every 5 min during each scan. The subject rated each sensation by moving a pointer along the scale, via a response box held in their right hand ([@bb0085]).

Blood glucose, plasma insulin, CCK and GLP-1 measurements {#s0045}
---------------------------------------------------------

Venous blood samples (10 ml) were collected into ice-chilled lithium heparin-treated tubes containing 400 kIU aprotinin per ml blood (Trasylol; Bayer Ltd., Berkshire, UK). Plasma was separated by centrifugation at 3000 rpm for 10 min at 4 °C within 1 h of collection, and stored at − 70 °C until assayed.

Venous blood glucose concentrations (mmol/l) were determined at the time of collection by the glucose oxidase method using a portable glucose meter (Medisense Optium Xceed, Abbott, Alameda CA USA). The accuracy of this method has been confirmed using the hexokinase technique ([@bb0065]).

Plasma insulin concentrations were determined using the ALPCO Insulin ELISA kit (ALPCO, Product number: 80-INSHU-E01.1, Salem, NH, USA). The sensitivity of the assay is 0.399 uIU/ml. The intra-assay coefficients of variability (CVs) were 5.1--10.3%, and the inter-assay CVs were 6.7--16.6%.

Plasma GLP-1 concentrations were determined using the ALPCO GLP-1 (7--36) and GLP-1 (9--36) ELISA kit (ALPCO, Product number: 43-GPTHU-E01, Salem, NH, USA). The assay has 0.01% cross-reactivity with GLP-1 and glucagon. The sensitivity of this assay is 0.06 pmol/l. The intra-assay CVs were 3.7--4.7%, and the inter-assay CVs were 6.2--9.5%.

Plasma CCK concentrations were determined using the ALPCO EURIA-CCK radioimmunoassay kit (ALPCO, Product number: 13-RB302). The assay has 0.5% cross-reactivity with gastrin-17 sulphated, and \< 0.01% with gastrin-17 non-sulphated. The sensitivity of the assay is 0.3 pmol/l. The intra-assay CVs were 2--5.5%, and the inter-assay CVs were 4.1--13.7%.

MRI acquisition {#s0050}
---------------

fMRI brain volumes were acquired at 5 second intervals for 30 min using a multi-slice, single-shot EPI sequence to achieve whole brain coverage: 40 axial slices, TR/TE = 5000/35 ms, voxel size = 1.8 × 1.8 × 3.5 mm, flip angle = 79°, SENSE acceleration factor = 1.8, matrix = 128 × 128, FOV = 240 × 240 mm. Daily quality assurance was carried out to ensure a consistent high signal-to-ghost ratio using an automated quality control procedure. A SENSE 8 channel head coil was used for radio frequency transmission and reception.

MRI image analysis {#s0055}
------------------

The fMRI data were analysed using Statistical Parametric Mapping (SPM8, [www.fil.ion.ucl.ac.uk/spm](http://www.fil.ion.ucl.ac.uk/spm){#ir0020}). Images were realigned, spatially normalised and smoothed to facilitate inter-subject averaging. The limits on head movement for inclusion were: 2 mm for x- and y-translation and 4 mm for z-translation, both per volume and across the whole scan, and 3° for yaw and 1.5° for roll and pitch, again per volume and across the whole scan.

First-level analysis was performed, using the p-block ph/physMRI analysis technique ([@bb0075; @bb0085; @bb0135; @bb0140]), on each subject for each study condition in the following ways: the pre- and post-infusion scans were split into two minute time-bins. The post-infusion scans were divided into 13 consecutive 2 minute time bins (T1--13) and the 24 scans from the 2 min immediately prior to the glucose/saline infusion formed the baseline time bin (T0). In each subject and condition, the signal averages for the 13 post-infusion time bins (T1--T13) were separately compared to the baseline average (T0) using regression within the general linear model framework. This resulted in 13 first level images corresponding to the BOLD signal change from baseline in each successive post-infusion time bin for each subject and condition. The realignment parameters for each session were included as regressors of no interest to correct for motion. Scanner drift was modelled using the scaling option for global normalisation in SPM. Contrast maps across time for glucose vs. saline and glucose vs. glucose + dex were calculated for each subject.

To determine whether statistically significant increments in the BOLD signal change from baseline across subjects occurred over time, two repeated-measures ANOVAs were used, one for the glucose vs. saline comparison and the other for the glucose vs. glucose + dex comparison, at a cluster-level statistical inference of p(False Discovery Rate; FDRc) \< 0.05 at a height threshold of p = 0.005.

Correlations were performed to determine relationships between changes in BOLD signal with blood glucose, plasma GLP-1 and insulin concentrations, and the subjective ratings of nausea, hunger and fullness. These were performed using the average values per subject (area under the curve (AUC) and across time) for each significant cluster extracted from the glucose vs. saline and glucose + dex vs. saline comparisons. For the AUC correlations, all time bin BOLD signal change contrasts were averaged per cluster and compared to the baseline corrected AUC blood concentrations for each individual. For the correlations with time, each cluster\'s average BOLD signal at five time bins (T + 5, T + 10, T + 15, T + 20 and T + 25 min) was calculated and correlated to the each subject\'s blood concentration measures at the same time points. This resulted in a correlation coefficient, r, for each subject. Each subject\'s r-values were then entered into a one-sample *t*-test. All correlations are reported at a False Discovery Rate level (pFDR \< 0.05) correcting for the number of cluster significant regions being tested.

Analysis of gastric emptying, blood glucose and GI hormone concentrations and appetite perceptions {#s0060}
--------------------------------------------------------------------------------------------------

Gastric emptying, blood glucose, plasma CCK, GLP-1 and insulin concentrations are displayed as raw data. VAS scores were analysed as change from baseline values. Areas under the curve were calculated for gastric emptying and blood glucose, CCK, GLP-1 and insulin concentrations using the trapezoidal rule. These data were analysed using repeated measures ANOVAs with treatment, and time (or for the AUC data, treatment) as factors. If ANOVAs revealed statistical significance, post-hoc paired comparisons, corrected for multiple comparisons using Bonferroni\'s correction, were performed. Statistical analysis was performed using SPSS Version 17.0. Data are presented as means (SEM).

Results {#s0065}
=======

The study was well tolerated by all participants. Due to difficulty obtaining blood samples from 2 of the participants while in the scanner, complete data sets for glucose, insulin, CCK and GLP-1 are available from only 10 participants. Three participants self-reported smoking ≤ three cigarettes/day. There were no apparent differences in gastric emptying, BOLD response or gut peptide secretion between the smokers and non-smokers, but this could not be formally evaluated due to the small numbers.

Gastric emptying {#s0070}
----------------

As in our previous study ([@bb0115]), we demonstrated an effect of treatment on gastric emptying (p = 0.003). Intragastric glucose slowed gastric emptying when compared with water (p = 0.017), and dexloxiglumide abolished this glucose-induced inhibition (p = 0.031), with no difference between the emptying of water and glucose + dex. The slower gastric emptying observed after glucose consumption is therefore CCK~1~-receptor dependent ([Fig. 1](#f0005){ref-type="fig"}A).

Gallbladder volumes {#s0075}
-------------------

There was an effect of intragastric glucose on gallbladder volume ([Fig. 1](#f0005){ref-type="fig"}B). Glucose decreased the volume of the gallbladder (p = 0.014) when compared with saline. As with gastric emptying, the effect of glucose was attenuated by dexloxiglumide pre-treatment (p = 0.008). This provides evidence of fully effective CCK~1~ receptor blockade by dexloxiglumide.

Areas of glucose-induced BOLD signal change {#s0080}
-------------------------------------------

Results of the one-way ANOVAs investigating the differences in BOLD signal responses over time following intragastric glucose (relative to saline) are presented in [Table 1](#t0005){ref-type="table"} and [Figs. 2 and 4](#f0010 f0020){ref-type="fig"}. A significant effect of time was observed in sections of the brainstem ([Figs. 4](#f0020){ref-type="fig"}A, B, C) and hypothalamus ([Fig. 4](#f0020){ref-type="fig"}D) (regions previously reported to show a positive BOLD response between lipid and saline ([@bb0075; @bb0085])), as well as the cerebellum, right fusiform and lingual gyri, insula/putamen, left parahippocampal gyrus, right middle temporal and thalamic regions. Investigation of the average time courses for these significant clusters highlighted that the effect of time was generally driven by an initial increase in BOLD signal followed by sharp decrease at 5 min ([Fig. 4](#f0020){ref-type="fig"}).

Effect of dexloxiglumide on areas of BOLD signal change {#s0085}
-------------------------------------------------------

Dexloxiglumide pre-treatment significantly modulated the BOLD signal response over time in the regions summarised in [Table 2](#t0010){ref-type="table"} and [Fig. 3](#f0015){ref-type="fig"}. Investigation of the average time courses for the significant clusters highlighted partial blockade of the effect of glucose to decrease BOLD signal in the hypothalamus ([Fig. 4](#f0020){ref-type="fig"}D). The supplementary motor area is of particular interest as this was the only region to show a positive BOLD response to glucose ingestion (glucose vs. saline) over time, an effect that was abolished by dexloxiglumide ([Fig. 4](#f0020){ref-type="fig"}E). Investigation of the average time course in the other brain regions in [Table 2](#t0010){ref-type="table"} showed that effect of time was driven in two separate ways: 1) for the cerebellum, left caudate, left and right cuneus, and left lingual gyrus, the effect of time was driven by the BOLD response for glucose + dex vs. saline being further reduced relative to glucose vs. saline, and 2) for the other regions the effect of time was driven by the initial glucose-induced increase in BOLD signal and subsequent sharp decrease at 5 min being abolished by dexloxiglumide pretreatment.

Time course of changes in BOLD signal {#s0090}
-------------------------------------

There were significant correlations between the time course of BOLD signal changes with the time course of changes in circulating blood glucose and insulin concentrations in all of the brainstem, hypothalamic, cerebellar, fusiform and thalamic regions responding to glucose ([Table 1](#t0005){ref-type="table"}). This temporal correlation was removed by pretreatment with dexloxiglumide in all of these regions, apart from the lateral cerebellum and the right occipital cortex (fusiform and lingual gyrus). A temporal correlation between the glucose + dex vs. saline BOLD signal with insulin was also observed in the left parahippocampal region. There were no significant correlations between BOLD signal changes with the AUC of blood glucose, GI hormones or subjective appetite measures. There were no significant temporal correlations between BOLD signal changes with GLP-1, or any of the subjective appetite measures.

With respect to clusters that showed a significant modulation of the glucose-induced BOLD signal by dexloxiglumide, there were correlations between the time course of the BOLD signal change with the time course of blood glucose and insulin concentrations in the hypothalamus, cerebellum, right putamen, left lingual gyrus and left precuneus ([Table 2](#t0010){ref-type="table"}). There were no temporal correlations between the time course for blood glucose and the time course for the glucose + dex vs. saline BOLD signal in any region, however, there were temporal correlations observed with insulin and GLP-1 in the cerebellum, bilateral cuneus and left lingual gyrus i.e. the clusters that showed an the effect of time driven by the BOLD response for glucose + dex vs. saline being further reduced in comparison to glucose vs. saline. Interestingly, in the supplementary motor area, where BOLD signal increased in response to glucose (and where the effect was reversed by dexloxiglumide), there was no temporal correlation with circulating blood glucose, insulin or GLP-1 concentrations ([Table 2](#t0010){ref-type="table"}). There were no significant correlations between BOLD signal changes and the AUC of blood glucose, hormones or subjective appetite measures. There were no significant temporal correlations with BOLD for any of the subjective appetite measures.

Blood glucose, plasma insulin, CCK and GLP-1 concentrations {#s0095}
-----------------------------------------------------------

### Glucose {#s0110}

There was an effect of treatment on blood glucose concentrations (p = 0.002). Both glucose (p = 0.001) and glucose + dex (p = 0.009) increased blood glucose concentrations when compared with saline, with no difference between glucose and glucose + dex (p = 1.000) ([Fig. 5](#f0025){ref-type="fig"}A).

### Insulin {#s0115}

There was an effect of treatment on the AUC for serum insulin concentrations (p \< 0.001). Both glucose (p = 0.003) and glucose + dex (p = 0.001) increased serum insulin concentrations when compared with saline. There was a treatment ∗ time interaction (p \< 0.001). Insulin concentrations were greater for glucose and glucose + dex between t = 5--25 min, when compared with saline, and greater for glucose + dex when compared with glucose at t = 25 min ([Fig. 5](#f0025){ref-type="fig"}B).

### CCK {#s0120}

There was an effect of treatment on the AUC for plasma CCK concentrations (p = 0.002). CCK was increased following glucose + dex when compared with glucose (p = 0.005) and saline (p = 0.007), with no differences between glucose and saline (p = 0.395) ([Fig. 5](#f0025){ref-type="fig"}C).

### GLP-1 {#s0125}

There was an effect of treatment on the AUC for plasma GLP-1 concentrations (p = 0.001) ([Fig. 5](#f0025){ref-type="fig"}D). Glucose increased plasma GLP-1 concentrations when compared with saline (p = 0.047), with no difference between glucose and glucose + dex, or glucose + dex and saline.

Perceptions of hunger, fullness and nausea {#s0100}
------------------------------------------

There were no differences in baseline ratings, nor any effect of any treatment, on perceptions of nausea ([Fig. 6](#f0030){ref-type="fig"}A) or hunger ([Fig. 6](#f0030){ref-type="fig"}B). There was an effect of treatment for fullness scores (p = 0.05). Glucose increased fullness when compared with saline (p = 0.009), with no differences between saline and glucose + dex ([Fig. 6](#f0030){ref-type="fig"}C).

Changes in fullness were not correlated to circulating levels of glucose, CCK, GLP-1 or insulin. Ratings of hunger were weakly related to plasma insulin (R = 0.36, P = 0.052), but not CCK, glucose or GLP-1, concentrations.

Discussion {#s0105}
==========

The development of whole brain fMRI applied to intragastric infusion of nutrients (physiological MRI; physMRI) has provided an entirely new means to understand the gut-to-brain signalling mechanisms regulating gastrointestinal function, appetite and food intake in humans ([@bb0075; @bb0085]). We have now, for the first time, demonstrated the whole brain responses to glucose when administered directly into the stomach to avoid the confounding effects of sight, taste or smell, and overcoming the technical issues associated with movement during swallowing. In the medulla, pons, and midbrain regions of the brainstem and in the hypothalamus (and other areas outlined in [Table 1](#t0005){ref-type="table"}) glucose, compared to the saline, decreased the BOLD signal at 5 min, after a small initial increase. The brainstem and hypothalamic regions have previously been identified to respond to intragastric lipid, using identical methods ([@bb0075; @bb0085]). However, in response to glucose, the decrease in BOLD signal was temporally correlated to the increases in blood glucose and plasma insulin concentrations.

Since CCK clearly mediated gastric and gall bladder emptying following intragastric glucose, the role of CCK in the CNS response to intragastric infusion of glucose was investigated using a pretreatment with dexloxiglumide (a CCK~1~ receptor antagonist). Investigation of the interaction between glucose and glucose + dex over time revealed several interesting results. There was a partial blocking of the effect of glucose to decrease BOLD signal in the hypothalamus by dexloxiglumide. Dexloxiglumide furthermore abolished the effect of glucose in the motor cortex, the only region to show a BOLD signal increase in response to glucose. In the cerebellum, left caudate, bilateral cuneus and left lingual gyrus, dexloxiglumide pre-treatment further reduced the glucose BOLD response. Interestingly, there was a significant temporal correlation with insulin and GLP-1 in all these regions apart from the left caudate. For the remaining regions dexloxiglumide changed the temporal characteristics of the glucose response by abolishing the initial increase in BOLD signal as observed for glucose vs. saline.

With regard to the areas showing decreased BOLD signal, our observations confirm previous reports of a decrease in BOLD signal within the hypothalamus following either oral or intravenous glucose in humans ([@bb0125; @bb0130; @bb0170; @bb0175; @bb0180; @bb0195]), and rats ([@bb0020; @bb0185]), and for the first time define the brainstem response to the presence of glucose in the GI tract in humans. In seeking to explore candidate pathways for these effects of glucose to decrease BOLD signal in the CNS regions outlined in [Table 1](#t0005){ref-type="table"}, our dexloxiglumide data indicate that, unlike the response to lipid ([@bb0085]), the response to glucose in these regions is not solely dependent on the activation of CCK~1~ receptors on vagal afferents. Even though we demonstrated that glucose does activate processes known to be CCK-dependent (i.e. dexloxiglumide reversible gallbladder contraction and slowing of gastric emptying ([@bb0040; @bb0115; @bb0145])), there was no significant effect of dexloxiglumide on BOLD signal reduction in these regions. This suggests that although glucose is likely to have activated a subset of neurons via the CCK~1~ receptor (as demonstrated by the dexloxiglumide sensitive increase in BOLD signal in cortical areas and possibly the small initial rise in BOLD signal observed prior to the decrease in the brainstem), there was also an additional, perhaps more direct, inhibitory action of circulating glucose and insulin, which may have occurred at the level of peripheral vagal afferents, and/or the brainstem and hypothalamus. This is supported by the observation that in rats, BOLD signal responses in the lateral hypothalamus, as well as other brain regions, to post-oral glucose were the same in both intact and vagotomised rats, whereas BOLD signal responses to glutamine were attenuated in vagotomised rats. This suggests that specific responses occur to different types of nutrients, with vagal activity being critical for the sensing of glutamine and lipid ([@bb0085]), and humoral factors, such as insulin, as well as changes in circulating glucose levels, being important for glucose detection ([@bb0190]). To this effect a direct comparison of our independent studies using intragastric lipid and glucose has been provided as supplementary data.

It is recognised that elevated glucose levels can directly influence the activity of specific glucose-sensing neurons in hypothalamic and brainstem regions ([@bb0100]), and that there are subsets of neurons in which elevated glucose levels are either excitatory or inhibitory ([@bb0055; @bb0100]). In addition, elevated blood glucose may have been signalling to the brain via activation (excitation or inhibition) of peripheral glucose-sensing neurons in the nodose ganglia ([@bb0055]). Animal studies strongly indicate that vago-vagal pathways play an important role in the regulation of gastrointestinal motility ([@bb0205]) and eating behaviour ([@bb0050]) in response to acute changes in blood glucose levels. Additionally, acute increases in glucose levels modulate synaptic connections between vagal afferent nerve terminals and neurons in the nucleus tractus solitarius ([@bb0200]). However, while one study has demonstrated an effect of intravenous glucose on BOLD signal in the hypothalamus ([@bb0180]), this effect was not replicated by others, despite inducing comparable increases in blood glucose concentrations ([@bb0160]). A number of studies have reported no relationship between blood glucose concentrations and glucose-induced changes in BOLD signal in the hypothalamus ([@bb0170; @bb0180]). Here, we have demonstrated a strong correlation between the timing of changes in blood glucose and plasma insulin levels, and the decrease in BOLD signal, suggesting that changes in circulating glucose and insulin concentrations are likely to be key mediators of the central response to glucose, rather than direct vagal afferent signalling from the gut.

While we did demonstrate that dexloxiglumide accelerated gastric emptying of glucose, this was not of a sufficient magnitude to modulate circulating glucose or insulin levels, and indeed, in the CNS regions in which we observed a significant relationship with glucose and insulin (i.e. those regions in which BOLD signal decreased), there was no difference in effect between glucose and glucose + dex conditions. Hence, gastric emptying rate is unlikely to be a major determinant of the CNS response reported here.

It appears from our data that the onset of the BOLD signal rise in the motor cortex was rapid, occurring within 5 min post-infusion and before any measurable elevation of plasma glucose. Further analysis of the direct comparison between glucose and lipid BOLD responses, using a two-way repeated measures ANOVA with nutrient (vs. saline) as a between subject factor and time as a within subject factor, highlighted the spatial similarity and temporal interaction between glucose and lipid ([@bb0075; @bb0085]) related changes in BOLD signal (Supplementary material). The data included in this comparison were collected in parallel on the same scanner with the same imaging parameters during the same time period. The motor cortex was not significant in this analysis due to a lack of direct overlap in the motor cortex for glucose and lipid however the time course for lipid from the motor cortex in [Fig. 3](#f0015){ref-type="fig"}D from [@bb0085] and in [Fig. 4](#f0020){ref-type="fig"}A in this paper are very similar (Supplementary Fig. 1A). Previous studies have also demonstrated that cortical areas (including the motor cortex) display an increase in BOLD signal during intravenous glucose ([@bb0160]). That this response was blocked by dexloxiglumide suggests that the early changes in BOLD signal were mediated by a peripheral vagal CCK~1~ receptor-dependent pathway. This is supported by a recent study that identified a positive relationship between changes in BOLD signal in the thalamus, amygdala, caudate, insula and orbitofrontal cortex with changes in plasma CCK concentrations following oral glucose ingestion ([@bb0105]). The current study however went beyond pure observation and utilised the CCK~1~ receptor antagonist dexloxiglumide, which we have previously shown to abolish the effect of lipid. Therefore this correlation cannot be causal: the fact that BOLD changes are in opposing directions in our study would make an identical signalling molecule driving both rather implausible. We validated that CCK activity was fully blockaded in our study by demonstrating the abolition of glucose-induced gallbladder contraction: measuring peripheral blood levels of CCK is clearly a poor assay of biological activity in this system, since much of the effects of CCK occur at a paracrine level within the gut. Where possible, physiology is better explored by using interventions such as receptor blockade.

It therefore appears that the effects of intestinal glucose are mediated by at least two nutrient sensing pathways in the CNS, both of which may modify appetite, eating behaviour and digestive function either directly (e.g. central detection of circulating insulin/glucose concentrations) or indirectly (e.g. activation of vagal afferents via gut peptides).

It should also be noted that intragastric infusion, while having benefits of ensuring consistent rate of nutrient delivery to the intestine and allowing a pure focus on gut-to-brain signals, does not entirely reflect normal meal ingestion due to the exclusion of oral and cephalic phases. For example, our analyses did not reveal relationships between BOLD signal changes with appetite perceptions. These analyses are likely to be underpowered since we were unable to collect blood from two participants while they were in the scanner. Additionally, subjective ratings of hunger and fullness in several subjects showed no change from pre-infusion baseline and, therefore, could not be correlated with BOLD responses. We ended up with data for n = 6 for hunger, and n = 7 for fullness, in these models. In the included subjects, the increase in fullness and reduction in hunger were very small in magnitude and blood and VAS scores were collected at 5 min intervals, therefore there was less temporal resolution in comparison to the initial BOLD analysis which was done using 2 minute time bins. The small magnitude of change in VAS scores was not unexpected, since it is well established that intragastric infusion has less potent effects on appetite perceptions than oral consumption ([@bb0015]). Future work using this paradigm should investigate the effects of these additional components during meal ingestion.

Of interest, it has recently been shown that GLP-1 in response to lipid is inhibited by dexloxiglumide indicating dependence on CCK receptor activation ([@bb0005]). This dependence does not appear to be the case in response to glucose stimulation and probably implicates a direct action of glucose on GLP-1 producing enteric mucosal cells.

The other brain regions responding to glucose, including the cerebellum, thalamus, precuneus and motor cortex have been consistently demonstrated in our previous studies to respond to nutrient ingestion and or gut hormones (i.e. ghrelin) ([@bb0075; @bb0085]), suggesting that they play a role in mediating the gastrointestinal and appetite responses to ingested food. In particular, the cerebellum has been shown to play an important role in food intake ([@bb0210]).

In conclusion this study provides important new information about whole brain responses to intragastric glucose in man, and demonstrates that multiple mechanisms operate to modulate BOLD signal in the nutrient-induced brain matrix.
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![(A) Gastric emptying (n = 3/12) and (B) change in gallbladder volume (n = 12) following intragastric glucose (1000 mOsmol), glucose (1000 mOsmol) + dexloxiglumide (600 mg) or saline/water control. Data are mean (SEM). \*glucose vs. water/saline, \^glucose + dex vs. glucose, p \< 0.05.](gr1){#f0005}

![Brain images showing areas exhibiting significant effect of time (pFDRc \< 0.05 at p \< 0.005) for glucose versus saline contrast. cb: cerebellum, pons/med: pons/medulla, mid: midbrain, hypo: hypothalamus, thal: thalamus, ling: lingual gyrus, phg: parahippocampal gyrus, put: putamen, ins: insula, mtg: middle temporal gyrus.](gr2){#f0010}

![Brain images showing areas exhibiting significant effect of time (pFDRc \< 0.05 at p \< 0.005) for glucose versus glucose + dex contrast. hypo: hypothalamus, put: putamen, caud: caudate, mc: motor cortex (SMA).](gr3){#f0015}

![Changes in blood-oxygenation-level-dependent (BOLD) signal over time in the medulla (A), pons (B), midbrain (C), and hypothalamus (D), and motor cortex (E), following bolus intragastric glucose (1000 mOsmol) and glucose + dex, relative to saline.](gr4){#f0020}

![Blood glucose (A) and plasma insulin (B), cholecystokinin (CCK) (C) and glucagon-like peptide-1 (GLP-1) (D) concentrations following bolus intragastric glucose (1000 mOsmol), glucose + dexloxiglumide, or saline (0.9%). \*glucose vs. saline, p \< 0.01, \^glucose + dex vs. saline, p \< 0.001, \#glucose vs. glucose + dex, p \< 0.05, n = 10.](gr5){#f0025}

![Effects of saline, glucose and glucose + dexloxiglumide on perceptions of nausea (A), hunger (B) and fullness (C). There were no differences in baseline ratings, nor any effect of any treatment, on perceptions of nausea or hunger. There was an effect of treatment for fullness scores (p = 0.05). Glucose increased fullness when compared with saline (p = 0.009), with no differences between saline and glucose + dex. \*P \< 0.05 glucose vs. saline.](gr6){#f0030}

###### 

Significant central nervous system clusters exhibiting effect of time between glucose and saline infusions: p(FDRc \< 0.05) at p = 0.005. TD --- Talairach Daemon; pFDRc --- cluster size False Discovery Rate p-value; CoM --- centre of mass; x,y,z {mm} --- Montreal Neurological Institute (MNI) coordinates from anterior commissure origin; wrt --- with respect to.

  Cluster-level statistics   (Glucose vs saline) ∗ time   CoM                          Glucose vs saline correlation wrt time   Glucose + dex vs saline correlation wrt time                                  
  -------------------------- ---------------------------- ---------------------------- ---------------------------------------- ---------------------------------------------- ------ ------- ------- ------- -------
  61                         0.045                        Brainstem--medulla L + R     1                                        − 43                                           − 47   0.034   0.055   ns      ns
  77                         0.023                        Brainstem--pons L + R        3                                        − 39                                           − 36   0.030   0.055   ns      ns
  121                        0.004                        Brainstem--midbrain L + R    2                                        − 34                                           − 19   0.013   0.026   ns      ns
  104                        0.007                        Hypothalamus L + R           2                                        − 3                                            − 12   0.007   0.004   ns      ns
  111                        0.006                        Cerebellum--anterior L + R   − 2                                      − 42                                           − 33   0.012   0.019   ns      ns
  357                        \< 0.001                     Cerebellum L                 − 23                                     − 56                                           − 41   0.012   0.019   0.062   0.042
  177                        \< 0.001                     Cerebellum R                 17                                       − 52                                           − 22   0.026   0.029   0.070   0.037
  95                         0.011                        Fusiform_R                   30                                       − 73                                           − 9    0.012   0.017   0.026   0.005
  76                         0.024                        Lingual_R                    10                                       − 71                                           − 7    ns      ns      0.050   0.009
  42                         0.099                        Insula_L/putamen_L           − 27                                     − 15                                           7      ns      ns      ns      ns
  68                         0.033                        Insula_R/putamen_R           35                                       − 17                                           2      ns      ns      ns      ns
  71                         0.030                        Parahippocampal_L            − 17                                     − 3                                            − 22   ns      ns      ns      0.049
  59                         0.049                        Temporal_Mid_R               53                                       − 45                                           5      ns      ns      ns      ns
  60                         0.047                        Thalamus_L                   − 17                                     − 28                                           3      0.058   ns      ns      ns
  47                         0.080                        Thalamus_R                   11                                       − 26                                           1      0.029   ns      ns      ns

###### 

Significant central nervous system clusters exhibiting effect of time between glucose infusion and glucose infusion following pretreatment with dexloxiglumide p(FDRc \< 0.05) at p = 0.005. TD --- Talairach Daemon; qFDRc --- cluster size False Discovery Rate q-value; CoM --- centre of mass; x,y,z {mm} --- Montreal Neurological Institute (MNI) coordinates from anterior commissure origin; wrt --- with respect to.

  Cluster-level statistics   (Glucose vs glucose + dex)\*time   CoM                     Glucose vs saline correlation wrt time   Gluc + dex vs saline correlation wrt time                                       
  -------------------------- ---------------------------------- ----------------------- ---------------------------------------- ------------------------------------------- ------ ------- ------- ---- ------- -------
  71                         0.031                              Hypothalamus L + R      4                                        − 1                                         − 13   0.005   0.004   ns   ns      ns
  1027                       0.000                              Cerebellum L + R        − 2                                      − 53                                        − 23   0.031   0.048   ns   0.026   0.045
  93                         0.014                              Caudate_L               − 14                                     21                                          0      ns      ns      ns   ns      ns
  119                        0.005                              Cingulum_Mid_L          − 10                                     − 27                                        37     ns      ns      ns   ns      ns
  62                         0.043                              Cuneus_L                − 14                                     − 76                                        31     ns      ns      ns   0.024   0.022
  150                        0.002                              Cuneus_R                13                                       − 78                                        27     ns      ns      ns   0.035   0.016
  119                        0.005                              Insula_L/Putamen_L      − 39                                     − 18                                        8      ns      ns      ns   ns      ns
  89                         0.016                              Insula_R/Putamen_R      22                                       11                                          − 7    0.003   0.011   ns   ns      ns
  184                        \< 0.001                           Lingual_L               − 15                                     − 68                                        − 7    0.030   0.038   ns   0.035   0.030
  80                         0.022                              Occipital_Inf_R         36                                       − 76                                        − 8    ns      ns      ns   ns      ns
  104                        0.009                              Parahippocampal_L       − 16                                     − 37                                        − 1    ns      ns      ns   ns      ns
  72                         0.030                              Parietal_Sup_L          − 18                                     − 59                                        45     ns      ns      ns   ns      ns
  65                         0.039                              Parietal_Sup_R          16                                       − 65                                        52     ns      ns      ns   ns      ns
  71                         0.031                              Precuneus_L             − 13                                     − 52                                        17     0.029   0.045   ns   ns      ns
  127                        0.004                              Precuneus_R             14                                       − 68                                        46     ns      ns      ns   ns      ns
  63                         0.042                              Supp_Motor_Area_L + R   7                                        15                                          53     ns      ns      ns   ns      ns
  130                        0.004                              Temporal_Mid_R          52                                       − 47                                        4      ns      ns      ns   ns      ns
  63                         0.042                              Thalamus_L              − 17                                     − 27                                        5      ns      ns      ns   ns      ns

[^1]: Present address: Boden Institute of Obesity, Nutrition, Exercise and Eating Disorders, Sydney Medical School, University of Sydney, Sydney, NSW, Australia, 2006.

[^2]: Joint first-authors.
